B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

CDC42BPB

MOLECULAR TARGET

CDC42 binding protein kinase beta

UniProt: Q9Y5S2NCBI Gene: 957817 compounds

CDC42BPB (CDC42 binding protein kinase beta) is targeted by 17 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting CDC42BPB

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1sb 2035804.92136
2alvocidib4.5291
3foretinib4.3476
4vandetanib4.3073
5nilotinib4.1764
6doramapimod4.0657
7sb 2021903.6437
8tae 6843.4330
9lestaurtinib3.0420
10gsk 6906932.6413
11zotiraciclib2.5612
12decernotinib2.208
13y 399832.208
14ucn 011.795
15sar 407899 free base1.795
16Axitinib0.691
17Dasatinib0.691

About CDC42BPB as a Drug Target

CDC42BPB (CDC42 binding protein kinase beta) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 17 compounds with documented CDC42BPB interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

CDC42BPB inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.